iOmx Therapeutics Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 56

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $76.3M

  • Investors
  • 7

iOmx Therapeutics General Information

Description

Developer of cancer therapeutics designed to address the immune checkpoint modulators on tumor cells. The company's therapeutics focuses on systematically screening human tumor cells, breaking down the inherent resistance mechanisms of tumors against immune attack often mediated by cell surface molecules that stimulate immune-inhibitory receptors on T cells, enabling healthcare institutions to offer cancer immune-checkpoint therapy.

Contact Information

Website
www.iomx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Fraunhoferstrasse 22
  • Martinsried
  • 82152 Munich
  • Germany
+49 089
Primary Industry
Drug Discovery
Corporate Office
  • Fraunhoferstrasse 22
  • Martinsried
  • 82152 Munich
  • Germany
+49 089

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

iOmx Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series B) 05-Oct-2021 $76.3M Completed Clinical Trials - Phase 2
2. Early Stage VC (Series A) 22-Sep-2016 Completed Clinical Trials - Phase 2
1. University Spin-Out 26-Apr-2016 Completed Clinical Trials - Phase 2
To view iOmx Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

iOmx Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of cancer therapeutics designed to address the immune checkpoint modulators on tumor cells. The company's ther
Drug Discovery
Munich, Germany
56 As of 2024

Philadelphia, PA
 

Geneva, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

iOmx Therapeutics Competitors (71)

One of iOmx Therapeutics’s 71 competitors is Aro Biotherapeutics, a Venture Capital-Backed company based in Philadelphia, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aro Biotherapeutics Venture Capital-Backed Philadelphia, PA
Amal Therapeutics Formerly VC-backed Geneva, Switzerland
Marengo Therapeutics Venture Capital-Backed Cambridge, MA
Noveome Biotherapeutics Venture Capital-Backed Pittsburgh, PA
Kite Pharma Formerly VC-backed Santa Monica, CA
You’re viewing 5 of 71 competitors. Get the full list »

iOmx Therapeutics Patents

iOmx Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026195655-A1 Antibodies targeting c-c chemokine receptor type 9 (ccr9) protein, and uses thereof Pending 17-Mar-2025
WO-2026003224-A2 Bispecific antigen binding proteins (abp) targeting immune checkpoint molecules and both leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2; combinations and uses thereof Pending 26-Jun-2024
WO-2026003224-A3 Bispecific antigen binding proteins (abp) targeting immune checkpoint molecules and both leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2; combinations and uses thereof Pending 26-Jun-2024
EP-4643861-B1 A halogenated heteroaryl kinase inhibitor for use in treating angiosarcoma Active 30-Apr-2024
EP-4643861-A1 A halogenated-heteroaryl kinase inhbitor for treating soft tissue sarcoma and vascular tumors Active 30-Apr-2024 A61P35/00
To view iOmx Therapeutics’s complete patent history, request access »

iOmx Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

iOmx Therapeutics Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Athos Service Family Office Minority
MIG AG Venture Capital Minority
MPM BioImpact Venture Capital Minority
M Ventures Corporate Venture Capital Minority
Sofinnova Partners Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

iOmx Therapeutics FAQs

  • When was iOmx Therapeutics founded?

    iOmx Therapeutics was founded in 2016.

  • Where is iOmx Therapeutics headquartered?

    iOmx Therapeutics is headquartered in Munich, Germany.

  • What is the size of iOmx Therapeutics?

    iOmx Therapeutics has 56 total employees.

  • What industry is iOmx Therapeutics in?

    iOmx Therapeutics’s primary industry is Drug Discovery.

  • Is iOmx Therapeutics a private or public company?

    iOmx Therapeutics is a Private company.

  • What is iOmx Therapeutics’s current revenue?

    The current revenue for iOmx Therapeutics is .

  • How much funding has iOmx Therapeutics raised over time?

    iOmx Therapeutics has raised $121M.

  • Who are iOmx Therapeutics’s investors?

    Athos Service, MIG AG, MPM BioImpact, M Ventures, and Sofinnova Partners are 5 of 7 investors who have invested in iOmx Therapeutics.

  • Who are iOmx Therapeutics’s competitors?

    Aro Biotherapeutics, Amal Therapeutics, Marengo Therapeutics, Noveome Biotherapeutics, and Kite Pharma are some of the 71 competitors of iOmx Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process